[go: up one dir, main page]

WO1997035570A1 - Utilisation d'acides monocarboxyliques insatures pour lutter contre des surinfections - Google Patents

Utilisation d'acides monocarboxyliques insatures pour lutter contre des surinfections Download PDF

Info

Publication number
WO1997035570A1
WO1997035570A1 PCT/EP1997/001471 EP9701471W WO9735570A1 WO 1997035570 A1 WO1997035570 A1 WO 1997035570A1 EP 9701471 W EP9701471 W EP 9701471W WO 9735570 A1 WO9735570 A1 WO 9735570A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
skin
superinfections
derivatives
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/001471
Other languages
German (de)
English (en)
Inventor
Ghita LANZENDÖRFER
Florian Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of WO1997035570A1 publication Critical patent/WO1997035570A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0212—Face masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • Superinfections of the type described above are, for example, secondary diseases which frequently occur in the full screen of AIDS. In itself - at least in low bacterial densities - harmless, but possibly also In this way, extremely pathogenic germs overgrow the healthy skin flora. With AIDS, however, other body organs are also affected by superinfections.
  • Such superinfections are also used in a variety of dermatological diseases, e.g. Atopic eczema, eczema, acne, seborrheic dermatitis or psoriasis are observed.
  • Many medical and therapeutic measures such as radio or chemotherapy for tumor diseases, caused as a side effect, drug-induced immunosuppression or systemic antibiotic treatment, as well as external chemical or physical influences (e.g. environmental pollution, smog), promote the occurrence of superinfections external and internal organs, especially the skin and mucous membranes.
  • topically administered antibiotics have the disadvantage that they not only free the skin flora from the secondary pathogen, but also severely impair the physiological skin flora and the natural healing process is slowed down again in this way.
  • the object of the present invention was to eliminate the disadvantages of the prior art and to make available substances and preparations containing such substances, the use of which can cure superinfections, the physiological skin flora not suffering any appreciable losses.
  • the invention relates to the use of one or more monounsaturated or polyunsaturated monocarboxylic acids or their derivatives or oils containing them as active ingredients against superinfections, in particular superinfections of the skin.
  • the monocarboxylic acids preferably contain 10 to 24 carbon atoms and 1 to 5 double bonds.
  • the invention also relates to cosmetic and dermatological preparations which contain these active ingredients. Topical preparations are preferred.
  • Mono- or polyunsaturated fatty acids and their derivatives are preferred.
  • Preferred monocarboxylic acids or fatty acids contain 14 to 24, in particular 16 to 22, carbon atoms. They can have one, two, three, four or five double bonds.
  • Preferred derivatives are monoglycerides, diglycerides or triglycerides of the carboxylic acids according to the invention and also their mixtures and also oils, in particular natural oils, which contain these active ingredients.
  • Active substances according to the invention are also the natural oils which contain the active substances mentioned.
  • Currant seed oil especially black currant
  • primrose seed oil borage oil, currant seed oil and other oils with a high content of gamma linolenic acid are particularly preferred.
  • the active compounds according to the invention can be used as free carboxylic acids or also as their salts with inorganic or organic cations. Suitable are e.g. Sodium, potassium, magnesium, calcium, aluminum, zinc or ammonium salts and the primary, secondary or tertiary alkylammonium salts, in particular the cations with the radicals H, methyl and / or ethyl.
  • esters of the carboxylic acids according to the invention with saturated or mono- or polysubstituted, in particular di- or trisaturated, unsaturated alkanols with in particular 1 to 24, preferably 1 to 12 carbon atoms, it being possible for the alkyls to be straight-chain or branched.
  • Suitable alkyls are e.g. Methyl, ethyl, n- or iso-propyl, n- or iso- or tert-butyl.
  • the carboxylic acids according to the invention can also be used in the form of their amides, which can be unsubstituted or substituted.
  • - to Cs-alkyl radicals are suitable.
  • Further suitable acid substituents of the carboxylic acid group are phospholipids, ceramides, cerebrosides, glycosphingolipids, lipoproteins and amino acids or their derivatives.
  • Alpha-linolenic acid and gammalinolenic acid and their derivatives are particularly preferred. It can also be used as described as a salt, mono-, di- or triglyceride or alkyl ester, e.g. as an ethyl ester.
  • the active compounds according to the invention and the preparations obtained therewith are outstandingly effective against superinfections, in particular the skin, which are caused by microorganisms, parasites and protozoa.
  • the microorganisms include e.g. eukaryotic and prokaryotic unicellular organisms, mycota and viruses.
  • Bacteria belong to the prokaryotic unicellular organisms. They can be roughly differentiated according to their shape (ball, cylinder, curved cylinder) and the structure of their cell wall (gram-positive, gram-negative). Finer subdivisions also take into account the physiology of the organisms. So there are aerobic, anaerobic and facultative anaerobic bacteria. Some individuals are of medical importance in their capacity as pathogenic germs, while others are completely harmless.
  • Antibiotics for example, which is not applicable to all antimicrobial substances, can be dated to the year 1941, although the first findings on penicillin were found as early as 1929. Antibiotics in today's sense are not for all medical purposes, least of all not suitable for cosmetic applications, since often the warm-blooded organism, e.g. the sick patient, is impaired in its metabolic functions when used in any way.
  • An object of the present invention was therefore to enrich the state of the art in this direction, in particular to provide substances which are effective against gram-positive and / or gram-negative bacteria without the use of the substances having an unacceptable adverse effect on health of the user would be connected.
  • Gram-negative germs are, for example, Escherichia coli, Pseudomonas species and Enterobacteriaceen, such as Citrobacter.
  • Gram-positive germs also play a role in cosmetics and dermatology.
  • bacterial secondary infections are of etiological importance in addition to other influences.
  • One of the main microorganisms associated with blemished skin is Propionibacterium acnes.
  • mycobionts include, for example, yeast (Protoascomycetes), mold (Plectomycetes), powdery mildew (Pyrenomycetes), downy mildew (Phycomycetes) and the mushrooms (Basidiomycetes).
  • Fungi are not plant organisms, but like them, they have a cell wall, vacuoles filled with cell sap, and a microscopically visible plasma flow. They contain no photosynthetic pigments and are C-heterotrophic. They grow under aerobic conditions and gain energy through the oxidation of organic substances. However, some representatives, such as yeasts, are optional anaerobes and are capable of generating energy through fermentation processes.
  • Dermatomycoses are diseases in which certain types of fungi, especially dermatophytes, penetrate the skin and hair follicles.
  • the symptoms of dermatomycoses are, for example, blisters, exfoiiation, rhagades and erosion, mostly associated with itching or allergic eczema.
  • Dermatomycoses can essentially be divided into the following four groups: dermatophytias (e.g. epidermophytia, favus, microsporie, trichophytia), yeast mycoses (e.g. pityriasis and other pityrosporum-related mycoses, Candida infections, blastomycosis, Busse-Buschke disease, Torba, Posephiedra , Torulopsidosis, trichosporosis), mold mycoses (e.g. aspergillosis, cephaiosporidosis, phycomycosis and scopulariopsidosis), system mycoses (e.g. chromomycosis, coccidiomycosis, histoplasmosis).
  • dermatophytias e.g. epidermophytia, favus, microsporie, trichophytia
  • yeast mycoses e.g.
  • Pathogenic and facultatively pathogenic germs include, for example, from the group of yeasts Candida species (for example Candida albicans) and those of the Pityrosporum family.
  • a participation of Pityrosporum ovale in the development of psoriasis is discussed by experts.
  • Dermatophytia almost exclusively affect skin, hair and nails. Hefemycoses can also affect mucous membranes and internal organs; systemic mycoses regularly extend to entire organ systems.
  • the areas of the body where clothing, jewelry or footwear can accumulate moisture and heat are particularly often affected.
  • the athlete's foot is one of the best known and most widespread dermatomycoses. Fungal diseases of the finger and toenail areas (onychomycoses) are particularly unpleasant.
  • Protozoans are parasitic single-celled organisms with a clearly delineated cell nucleus that reproduce sexually (by two or four division and budding), or sexually (Gameto, Gamonto and autogamy). Food is taken in from the environment by permeation and by pinocytosis or phagocytosis. Most protozoa can develop vegetative, mostly mobile states (so-called trophozoites) under unfavorable circumstances, cysts as permanent forms,
  • protozoa are divided into four different groups:
  • Trichomoniasis (caused by Trichomonas vaginalis), Lamblienruhr (caused by Lamblia intestinalis), visceral as well as cutaneous and mucosal leishmaniasis (caused for example by Leishmania donovanii, L. tropica, L.brasiliensana, L-mexico L.diffusa or L.
  • trypanosmiasis caused by different types of Trypanosoma
  • amoebic dysentery and amebiasis caused by different types of Entamoeba, Jodamoeba butschiii or Naegleria fowleri
  • coccidosis caused by Isospora belli
  • balantid dysentery Balantidium coli
  • the way of life is either aprophytic or purely parasitic, possibly only as a periodic, temporary or stationary parasite.
  • the development of parasites is linked to one or more different host organisms, and humans can be intermediate hosts or end hosts.
  • Medically and dermatologically significant parasites are, for example, the helminths, which in turn are subdivided into Trematodae, Cestodae and Nematodae.
  • Helminthoses that impair human well-being include, for example, schistosomiasis (caused by Schistosoma species), tapeworm infestation from the intestine and other internal organs (caused by e.g. Taenia species and Echinococcus species), Ascariasis (caused by Ascaris lumbricoides), Enterobiasis (caused by Enterobium vermicularis), paragonimiasis (caused by Paragonium species), fiiariosis (caused e.g. by Wucheria bancrofti) and other nematode infestations (e.g. caused by Trichuris trichura or Trichinella spiralis).
  • schistosomiasis caused by Schistosoma species
  • tapeworm infestation from the intestine and other internal organs caused by e.g. Taenia species and Echinococcus species
  • Ascariasis caused by Ascaris lumbricoides
  • Enterobiasis caused by Enterobium
  • Pediculoides ventricosus scabies (caused by Sarcoptes scabii), fly and / or fly larvae (caused by Glossina, Stomoxys, Tabanus, for example) , Chrysops, Lucilia, Chrysomya, Cochliamya, Wohlfartia, Cordylobia or Dermatobia species), mosquito and / or mosquito larvae (caused, for example, by Aedes-Culex, Anopheles, Phlebotomus-Culicuides-, Sumilium- or Haemagoges species), tick infestation (caused, for example, by Argas persicus and other Argas species, Ornithodorus erraticus and other Omithodorus species, Orobius Rhiphocephalus, Dermacentor, Haemaphysalis, Amblyomma, Ixodes species), Porocephalose (caused by Porocephalus Species), flea infestation (caused
  • the parsites living on or in the human organism can in turn be carriers of bacteria, mycota, protozoa and viruses, which can have a lasting effect on the health and well-being of the host organism, for example humans.
  • viruses according to the invention are mentioned below:
  • viruses are biological structures that require a host cell for biosynthesis.
  • Extracellular viruses also called “virions” consist of a single- or double-stranded nucleic acid sequence (DNA or RNA) and a protein coat (called capsid), optionally an additional lipid-containing envelope (envelope).
  • capsid protein coat
  • envelope optionally an additional lipid-containing envelope
  • the whole of nucleic acid and capsid is also nucleo-
  • the viruses were classified classically according to clinical criteria, but nowadays mostly according to their structure, their morphology, but especially according to the nucleic acid sequence.
  • Medically important virus types are, for example, influenza viruses (family of the Orthomyxoviridae), lyssaviruses (e.g.
  • rabies family of the rhabdoviruses
  • enteroviruses e.g. hepatitis A, family of the Picornaviridae
  • hepadnaviruses e.g. hepatitis B, family of the Hepadnaviridae
  • viruses There are no virucides, meaning virus-killing substances in the actual sense, since viruses do not have their own metabolism. For this reason, it was also discussed whether viruses should be classified as living beings. In any case, pharmacological interventions without damage to the unaffected cells is difficult. Possible mechanisms of action in the fight against the viruses are primarily the disruption of their replication, e.g. by blocking the enzymes which are important for replication and which are present in the host cell. Furthermore, the release of the viral nucleic acids into the host cell can be prevented.
  • antiviral or “effective against viruses”, “virucidal” or similar are understood to mean the property of a substance, a single-cell or multicellular organism against harmful consequences of a virus infection, be it prophylactic or therapeutic to protect, regardless of what the actual mechanism of action of the substance in individual cases.
  • the active compounds according to the invention are outstandingly effective against superinfections, in particular the skin, and in particular against those caused by staphylococci, pityrosporum oval and dermatophytes, yeasts or fungi.
  • the skin flora of a healthy person consists essentially of apothogenic staphylococci, the presence of which is supplemented by coryneform bacteria in some areas (armpit, genital area).
  • a variety of skin diseases e.g. atopic dermatitis, atopic dermatitis, neurodermatitis, psoriasis, immune deficiency due to immune suppression etc.
  • atopic dermatitis e.g. atopic dermatitis, atopic dermatitis, neurodermatitis, psoriasis, immune deficiency due to immune suppression etc.
  • pathogenic organisms occur in high numbers of germs.
  • gram-negative organisms e.g. Escherichia coli, Pseudomonas aeruginosa
  • yeasts in addition to P. ovale, e.g. Candida albicans
  • the active compounds according to the invention can also be used for the prevention of vaginal infections and for intimate hygiene.
  • topically effective antimicrobial formulations are used to alleviate the pathological changes mentioned above human skin
  • all of these formulations in addition to the active ingredients known therein, do not show any selectivity towards pathogenic staphylococci, but rather impair the overall flora in one and the same way.
  • pathogenic staphylococci especially Staph. aureus
  • Suitable cosmetic vehicles by topical administration of active ingredients according to the invention in suitable cosmetic vehicles, it is possible to selectively and selectively prevent the growth of pathogenic staphylococci on the skin and thus prevent the development of superinfections, for example in atopics, psoriasis and immunosuppressed patients.
  • suitable skin care with active ingredients according to the invention can prevent the more severe clinical manifestation of these diseases.
  • Suitable indications for use include the treatment of superinfections for atopic eczema, atopic dermatitis, neurodermatitis, psoriasis, immunosuppression (e.g.
  • UV, chemotherapy and radiation therapy or viral diseases (AIDS, herpes virus infections, varicella virus infections) and all other pathological diseases Changes in the skin, which are accompanied, for example, by the presence of pathogenic staphylococci.
  • suitable indications are changes in the skin flora induced by medication treatment, the use as accompanying therapy for treatment with corticosteroids or antifungals as well as the use as occupational safety cosmetics for occupations with high chemical or physical stress on the skin (e.g. beauticians, hairdressers).
  • the active compounds according to the invention can also be used when deodorants and antiperspirants are used.
  • the active compounds according to the invention and the cosmetic and dermatological preparations obtained therewith serve to maintain and restore a healthy skin flora, ie they can be used prophylactically and for the treatment of disorders. They are particularly useful for selectively influencing pathogenic skin germs, preferably pathogenic staphylococci, while protecting the skin natural skin flora, preferably apathogenic staphylococci, suitable. So they are very good for selective staph control. aureus with simultaneous protection of staph. suitable for epidermidis.
  • Preparations according to the invention containing the active substances according to the invention are particularly advantageously characterized in that the active substances according to the invention in concentrations of 0.01-99.9% by weight, in particular 0.05 to 50.00% by weight, preferably 0.1 5.0% by weight are present, in each case based on the total weight of the preparations.
  • the active compounds according to the invention can be incorporated into the usual cosmetic and dermatological preparations.
  • Well-suited preparations are, for example, emulsions such as O / W emulsions, W / O emulsions, each of which may have higher or lower viscosities, gels such as lipo-gels with different water and / or ethanol contents, lotions, fat lotions, ointments, oils such as Skin oils or bath oils, powders, lip care products such as lip care sticks, sun protection products, for example with UVA and / or UVB filters, products containing surfactants, e.g. for hair care or care of the scalp, shower and bath preparations, deodorant formulations and antiperspirants, masks, e.g. Face masks and decorative cosmetics.
  • surfactants e.g. for hair care or care of the scalp, shower and bath preparations, deodorant formulations and antiperspirants
  • masks e.g. Face masks and decorative cosmetics.
  • Cosmetic and dermatological preparations according to the invention can also be in the form of aerosols, that is to say from aerosol containers, squeeze bottles or preparations which can be sprayed by a pump device, or in the form of liquid compositions which can be applied by means of roll-on devices, but also in the form of from normal bottles and containers coatable W / O or O / W emulsions, e.g. Creams or lotions.
  • the preparations can advantageously be in the form of tinctures, shampoos, washing, showering or bathing preparations or powders.
  • lipid or fat-like substances such as oleic acid decyl ester, cetyl alcohol and cetylstearyl
  • skin care lipid or fat-like substances such as oleic acid decyl ester, cetyl alcohol and cetylstearyl
  • alcohol and 2-octyldodecanol in the proportions customary for such preparations, and slime-forming substances and thickeners, for example hydroxyethyl or hydroxypropyl cellulose, polyacrylic acid, polyvinylpyrrolidone, but also in small quantities cyclic silicone oils (polydimethylsiloxanes) and liquid polymethylphenylsiloxanes with lower viscosity.
  • Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • Non-ionic types such as polyoxyethylene fatty alcohol ethers, e.g. Cetylstearyl alcohol polyethylene glycol ethers with 12 or 20 attached ethylene oxide units per molecule, cetostearyl alcohol as well as sorbitan esters and sorbitan ester ethylene oxide compounds (e.g. sorbitan monostearate and polyoxyethylene sorbitan monostearate) and long-chain, higher molecular weight waxy polyglycol ethers have been found to be suitable.
  • polyoxyethylene fatty alcohol ethers e.g. Cetylstearyl alcohol polyethylene glycol ethers with 12 or 20 attached ethylene oxide units per molecule
  • cetostearyl alcohol as well as sorbitan esters and sorbitan ester ethylene oxide compounds (e.g. sorbitan monostearate and polyoxyethylene sorbitan monostearate) and long-chain, higher molecular weight waxy polyglycol ethers have been found to be suitable.
  • the preparations according to the invention can be perfume, dyes, antioxidants, suspending agents, buffer mixtures or other usual cosmetic or dermatological raw materials are added.
  • the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg anserine), carotenoids, carotenes (eg ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, lipoic acid and their derivatives (eg dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine , Cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl,
  • buthioninsulfoximines homocyste- insulfoximine, buthioninsulfones, penta-, hexa-, himinath
  • very low tolerable dosages e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • ⁇ -hydroxy acids e.g. citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin , Biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to use their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
  • the pH of the dermatological preparations according to the invention is less than 8. pH values that are slightly higher than 7 but less than 7.5 can generally be tolerated. In any case, for a given fatty acid mixture, it is easy to determine which exact upper pH limit has to be observed by simply trying it out, without inventive step.
  • the pH of the formulations according to the invention is advantageously adjusted to less than 8 in the acidic to very weakly alkaline range, preferably from 4.0 to 7.5, particularly preferably from 5.0 to 6.5.
  • auxiliary additives and carriers and possibly perfume to be used can easily be determined by a person skilled in the art by simply trying them out, depending on the type of product in question.
  • the preparations according to the invention are prepared in a customary manner, usually by simple mixing with stirring, if necessary with gentle heating. It has no difficulties.
  • the fat phase and the water phase are, for example, prepared separately, optionally with heating, and then emulsified.
  • the suspension bases for this can advantageously be selected from the group
  • Silica gels e.g. those available under the trade name Aerosil®
  • kieselguhr e.g. those available under the trade name Aerosil®
  • talc e.g. those available under the trade name Aerosil®
  • modified starch titanium dioxide
  • silk powder e.g. those available under the trade name silk powder
  • nylon powder e.g. those available under the trade name Aerosil®
  • polyethylene powder e.g. those available under the trade name Aerosil®
  • the constituents mentioned under a) are processed to a homogeneous solution and filled up with the water phase b).
  • the finished solution is filled into pump atomizers.
  • Roll-on emulsion% by weight a) 1, 3-butylene glycol 2 hydroxyethyl cellulose 0.5 b) water ad 100 c) ethanol 60 PEG-40-hydr. Castor oil 2 palmitoleic acid 0.3 perfume qs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'un ou de plusieurs acides monocarboxyliques insaturés une ou plusieurs fois ou de ses(leurs) dérivés ou d'huiles les contenant, comme principes actifs pour lutter contre des surinfections, notamment des surinfections de la peau.
PCT/EP1997/001471 1996-03-26 1997-03-22 Utilisation d'acides monocarboxyliques insatures pour lutter contre des surinfections Ceased WO1997035570A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19611953.7 1996-03-26
DE19611953A DE19611953A1 (de) 1996-03-26 1996-03-26 Verwendung von ungesättigten Monocarbonsäuren gegen Superinfektionen

Publications (1)

Publication Number Publication Date
WO1997035570A1 true WO1997035570A1 (fr) 1997-10-02

Family

ID=7789491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001471 Ceased WO1997035570A1 (fr) 1996-03-26 1997-03-22 Utilisation d'acides monocarboxyliques insatures pour lutter contre des surinfections

Country Status (2)

Country Link
DE (1) DE19611953A1 (fr)
WO (1) WO1997035570A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372425B2 (en) 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19832888A1 (de) * 1998-07-22 2000-01-27 Beiersdorf Ag Pflegende kosmetische und dermatologische Zubereitungen mit einem Gehalt an Fettsäuren
DE19930030B4 (de) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
GB2181349A (en) * 1985-10-07 1987-04-23 Rochas Parfums Skin care composition containing polyunsaturated fatty acids
EP0524796A1 (fr) * 1991-07-24 1993-01-27 Scotia Holdings Plc Utilisation d'acids gras essentiels pour la fabrication d'un médicament pour le traitement du SIDA
EP0598365A1 (fr) * 1992-11-18 1994-05-25 WOGEPHARM GmbH Agent pour le traitement d'un eczème atopique et d'autres maladies inflammatoires de la peau

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2151740C3 (de) * 1971-10-18 1975-03-13 Henkel & Cie Gmbh, 4000 Duesseldorf Haarkosmetische Mittel
DE2412160A1 (de) * 1974-03-14 1975-10-02 Henkel & Cie Gmbh Kosmetische mittel mit einem gehalt an proteinderivaten
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
FR2520253A1 (fr) * 1982-01-28 1983-07-29 Oreal Nouveau systeme emulsionnant a base d'un condensat de proteines, d'un sterol polyoxyethylene et de phosphatide et son utilisation en cosmetique
DE3507791A1 (de) * 1984-03-07 1985-09-26 Roshdy Ismail Mittel zum schutz der haut
DE3535084A1 (de) * 1985-10-02 1987-04-09 Roshdy Ismail Mittel zum schutz der haut
US4701471A (en) * 1986-04-16 1987-10-20 Loucks Sr Joseph Skin care composition
AU619256B2 (en) * 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
CH679119A5 (fr) * 1988-05-13 1991-12-31 Sandoz Ag
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
DE4432633C2 (de) * 1994-09-14 1997-07-31 Singer Peter Dr Med Priv Doz Pharmazeutisches Präparat zur lokalen Behandlung von Schuppenflechte, Neurodermitis und Ekzem

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
GB2181349A (en) * 1985-10-07 1987-04-23 Rochas Parfums Skin care composition containing polyunsaturated fatty acids
EP0524796A1 (fr) * 1991-07-24 1993-01-27 Scotia Holdings Plc Utilisation d'acids gras essentiels pour la fabrication d'un médicament pour le traitement du SIDA
EP0598365A1 (fr) * 1992-11-18 1994-05-25 WOGEPHARM GmbH Agent pour le traitement d'un eczème atopique et d'autres maladies inflammatoires de la peau

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLER S J ET AL: "IN VITRO AND IN VIVO ANTISTAPHYLOCOCCAL ACTIVITY OF HUMAN STRATUM CORNEUM LIPIDS", ARCHIVES OF DERMATOLOGY, vol. 124, no. 2, 1 February 1988 (1988-02-01), pages 209 - 215, XP000575011 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372425B2 (en) 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
US9072714B2 (en) 2008-10-31 2015-07-07 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament

Also Published As

Publication number Publication date
DE19611953A1 (de) 1997-10-02

Similar Documents

Publication Publication Date Title
DE19602108A1 (de) Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
EP0775478B1 (fr) Combinaisons d'agents actifs à base de glycérides partiels et d'acide acétique dialkylsubstitués
EP0869797A2 (fr) Utilisation des derives des glucides comme substances actives antimicrobiennes, antimycosiques et/ou antivirales
EP0806935A2 (fr) Principes actifs anti-adherents
DE19543695A1 (de) Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von alpha-Hydroxyalkansäuren und Squalen
WO2011038797A1 (fr) Utilisation de magnolol ou d'honokiol en tant que principes actifs antibactériens, antimycosiques, antiparasitaires ou antiviraux
DE19602111A1 (de) Gegen Bakterien, Mycota, Parasiten, Protozoen und Viren wirksame Zusammensetzungen auf der Basis von Squalen, Sphingolipiden und Fettsäuren
DE19541967A1 (de) Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von Partialglyceriden und Arylverbindungen
DE19634019A1 (de) Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
EP0821948A2 (fr) Combination d'agents actifs à base de glycérides partielles et d'acide acétique dialkylsubstitués ayant des propriétés antibactériennes, anti-mycotiques et anti-virales
EP0876137A1 (fr) Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus
DE10025124B4 (de) Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
EP2793820B1 (fr) Utilisation d'une association d'acide sorbique et d'un acide hydroxamique pour combattre les pellicules cappillaires.
DE19718777A1 (de) Verwendung von Estern aus Fettsäuren und Di- und Oligosacchariden gegen die Adhäsion von Mikroorganismen
DE19643585A1 (de) Antiadhäsive Sphingolipide
DE19634021A1 (de) Antiadhäsive Glycoglycerolipide
DE19826499A1 (de) Gegen Bakterien, Mycota, Viren, Parasiten und Protozoen wirksame Substanzen
DE19742275A1 (de) Estern verzweigtkettiger Carbonsäuren und verzweigtkettiger Alkohole als antibakterielle, antimycotische, antiparasitäre oder antivirale Wirkstoffe
WO1997035570A1 (fr) Utilisation d'acides monocarboxyliques insatures pour lutter contre des surinfections
EP0838155A1 (fr) Stéroides et leurs dérivés possédant des propriétés anti-adhésives
DE102011088944A1 (de) Wirkstoffkombinationen aus Silberverbindungen und einer oder mehreren physiologisch unbedenklichen Hydroxamsäure sowie kosmetische oder dermatologischeZubereitungen, solche Wirkstoffkombinationen enthaltend
DE19643586A1 (de) Gegen Mikroorganismen, Viren, Parasiten und Protozoen wirksame Sterole und Sterolderivate
DE10025122A1 (de) Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
EP1297829A1 (fr) Combinaison de principes actives à base des alcools polyhydriques et d'acides acétique dialkylsubstitués agissant contre des bacteries, des mycoses et des viruses
DE102011088957A1 (de) Wirkstoffkombinationen aus Pirocton Olamin und einer oder mehreren physiologischunbedenklichen Hydroxamsäure sowie kosmetische oder dermatologischeZubereitungen, solche Wirkstoffkombinationen enthaltend

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97534027

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase